Results 1 to 10 of about 352 (104)

Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia [PDF]

Yeungnam University Journal of Medicine, 2021
We report the case of a 16-month-old patient with chronic immune thrombocytopenia (ITP) patient who experienced delayed treatment-free response (TFR) after romiplostim treatment.
Hyun Ji Lim, Young Tae Lim, Jeong Ok Hah, Jae Min Lee   +3 more
doaj   +1 more source

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers

Pharmacology Research & Perspectives, 2023
Aims The pharmacodynamic (PD) similarity between GP40141, a proposed romiplostim biosimilar, and reference romiplostim was evaluated. Pharmacokinetics and safety were also assessed.
Igor Makarenko, Artem Dorotenko, Sergey Noskov, Veniamin Banko, Valeria Saparova, Alexandr Khokhlov, Evgeniia Zoreeva, Andrey Nedorubov, Bella Zinnatulina, Maria Gefen, Roman Drai   +10 more
doaj   +1 more source

Aplastic anemia with thrombopoietin gene mutation successfully treated with romiplostim monotherapy

Indian Pediatrics Case Reports, 2023
Background: Eltrombopag and romiplostim are thrombopoietin-receptor agonists (TPO-RA), which are approved globally for the treatment of immune thrombocytopenia.
Niranjan Gurunath Hegde, Deenadayalan Munirathnam, Meena Sivasankaran, Ravikumar Thangadorai   +3 more
doaj   +1 more source

Quality of Life Changes in Patients with Chronic Immune Thrombocytopenia in the Process of Romiplostim Therapy, its Efficacy and Safety in the Real-World Setting: Results of a Multi-Center Observational Study

Клиническая онкогематология, 2023
Aim. To study the quality of life in patients with chronic immune thrombocytopenia (ITP) in the process of romiplostim therapy and to assess the efficacy and safety of this drug in real-world setting. Materials & Methods.
T. I. Ionova, O. Yu. Vinogradova, T. V. Shelekhova, D. G. Sherstnev, A. V. Proidakov, E. V. Lyyurova, M. M. Pankrashkina, L. A. Mukha, E. E. Markova, N. V. Novitskaya, T. I. Pospelova, T. N. Babaeva, N. B. Bulieva, G. B. Kuchma, E. A. Andreevskaya, E. E. Zinina, M. V. Frolova, K. B. Trizna, I. L. Shestopalova, T. V. Shneider, S. A. Volkova, S. G. Zakharov, I. I. Mulina, I. E. Solov’eva, A. A. Myasnikov, A. A. Kuchin, L. B. Khvorostenko, N. M. Porfirieva, Tatyana Pavlovna Nikitina, V. V. Ptushkin, S. V. Gritsaev   +30 more
doaj   +1 more source

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review

Hematology, Transfusion and Cell Therapy, 2023
Objective: To evaluate the efficacy and safety of romiplostim (thrombopoietin-receptor agonist) in the treatment of pediatric immune thrombocytopenia (ITP).
Fernanda Lubiana de Oliveira, Fernanda Silva Sequeira, Marlene Pereira Garanito   +2 more
doaj   +1 more source

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use

Research and Practice in Thrombosis and Haemostasis, 2022
Background Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT.
Cy R. Wilkins, Jocelyn Ortiz, Leah J. Gilbert, Shen Yin, Jodi V. Mones, Rekha Parameswaran, Simon Mantha, Gerald A. Soff   +7 more
doaj   +1 more source

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies

Haematologica, 2020
Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy delays, dose reductions, and discontinuation. There is no FDA-approved agent available to manage CIT.
Hanny Al-Samkari, Aric D. Parnes, Katayoon Goodarzi, James I. Weitzman, Jean M. Connors, David J. Kuter   +5 more
doaj   +1 more source

Romiplostim-associated increase in CD34+ megakaryocytes in a case of immune thrombocytopenia: A case report

Human Pathology Reports, 2023
We report a patient with chronic immune thrombocytopenia purpura who underwent bone marrow biopsies before and after treatment with romiplostim. The biopsy after treatment with romiplostim showed a marked increase in the numbers of megakaryocytes which ...
Charles M. Lombard, Jiali Li, Bijayee Shrestha   +2 more
doaj   +1 more source

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Journal of Hematology & Oncology, 2012
Background Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of ...
Wang Eunice S, Lyons Roger M, Larson Richard A, Gandhi Sunil, Liu Delong, Matei Carmen, Scott Bart, Hu Kuolung, Yang Allen S   +8 more
doaj   +1 more source

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice

Pharmaceutics, 2022
Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited for ITP in pregnant women due to concerns about fetal toxicity.
Kensaku Nakai, Takuya Misugi, Kohei Kitada, Yasushi Kurihara, Mie Tahara, Akihiro Hamuro, Akemi Nakano, Masayasu Koyama, Yukimi Kira, Daisuke Tachibana   +9 more
doaj   +1 more source